Importantly for MNTA investors, Teva did not lower its guidance for 2012 Copaxone sales; rather Teva’s guidance remains at $3.8B, which suggests US Copaxone sales of approximately $2.6B (#msg-75407657). The $2.6B figure assumes no generic entry in the market, of course.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.